Pompe disease is a metabolic myopathy, due to deficiency of alpha glucosidase, with a wide clinical spectrum. Enzyme replacement therapy is the only available treatment to improve morbidity and mortality, especially in infantile-onset form. However, some patients experience infusion-associated reactions, which may restrict their access to this treatment. We report on two patients (respectively 12 and 3 months old) with infantile-onset Pompe disease and severe cardiomyopathy, that presented with severe reactions during infusion of enzyme replacement therapy and were successfully desensitized with a new individualized protocol. Our protocol, using microdilution and a premedication with antihistamines, corticosteroids, and tranexamic acid, seems safe and effective and it may allow the continuation of therapy in Pompe patients resulting in the reduction of morbidity and mortality related to this disease.

Desensitization of two young patients with infantile-onset Pompe disease and severe reactions to alglucosidase alfa / Gragnaniello, V.; Fecarotta, S.; Pecoraro, A.; Tarallo, A.; Catzola, Andrea; Spadaro, G.; Parenti, G.; Della Casa, R.. - In: NEUROLOGICAL SCIENCES. - ISSN 1590-1874. - 40:7(2019), pp. 1453-1455. [10.1007/s10072-019-03744-3]

Desensitization of two young patients with infantile-onset Pompe disease and severe reactions to alglucosidase alfa

Fecarotta, S.;Pecoraro, A.;CATZOLA, ANDREA;Spadaro, G.;Parenti, G.;Della Casa, R.
2019

Abstract

Pompe disease is a metabolic myopathy, due to deficiency of alpha glucosidase, with a wide clinical spectrum. Enzyme replacement therapy is the only available treatment to improve morbidity and mortality, especially in infantile-onset form. However, some patients experience infusion-associated reactions, which may restrict their access to this treatment. We report on two patients (respectively 12 and 3 months old) with infantile-onset Pompe disease and severe cardiomyopathy, that presented with severe reactions during infusion of enzyme replacement therapy and were successfully desensitized with a new individualized protocol. Our protocol, using microdilution and a premedication with antihistamines, corticosteroids, and tranexamic acid, seems safe and effective and it may allow the continuation of therapy in Pompe patients resulting in the reduction of morbidity and mortality related to this disease.
2019
Desensitization of two young patients with infantile-onset Pompe disease and severe reactions to alglucosidase alfa / Gragnaniello, V.; Fecarotta, S.; Pecoraro, A.; Tarallo, A.; Catzola, Andrea; Spadaro, G.; Parenti, G.; Della Casa, R.. - In: NEUROLOGICAL SCIENCES. - ISSN 1590-1874. - 40:7(2019), pp. 1453-1455. [10.1007/s10072-019-03744-3]
File in questo prodotto:
File Dimensione Formato  
Gragnaniello2019.pdf

solo utenti autorizzati

Tipologia: Documento in Post-print
Licenza: Dominio pubblico
Dimensione 165.56 kB
Formato Adobe PDF
165.56 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/752255
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 5
social impact